Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2021-03-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
自愿披露关于阿达木单抗注射液获得药品补充申请批准通知
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the approval of a supplemental drug application for 阿达木单抗注射液 (Adalimumab Injection) by the National Medical Products Administration of China. It details the approval notice, drug specifications, and risk warnings. The document is short (1371 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-23 Chinese
百奥泰独立董事关于第一届董事会第二十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of 百奥泰生物制药股份有限公司 regarding various board meeting agenda items, including profit distribution, remuneration plans, use of raised funds, appointment of senior management, and appointment of the accounting firm. It discusses approval and compliance with laws and regulations but does not contain financial statements or detailed financial data. The document is related to board/management decisions and approvals rather than a full report or announcement of financial results. Therefore, it fits best under Board/Management Information (MANG). The document length is 2061 characters, which is relatively short and consistent with a management or board announcement rather than a full report.
2021-03-17 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited (the sponsor) regarding the use of temporarily idle raised funds by Bio-Thera Solutions Ltd. It references regulatory guidelines and approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document includes specifics about the amount of funds raised, their intended use, board and supervisory approvals, independent director opinions, risk control measures, and the sponsor's verification opinion. It is a formal verification and audit-type report on the use of raised funds, not a general annual or quarterly report, nor a simple announcement. The document length (6289 characters) and content indicate it is a standalone audit or verification report related to the use of funds, consistent with an Audit Report / Information filing rather than a report publication announcement or regulatory filing. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2021
2021-03-17 Chinese
百奥泰独立董事关于第一届董事会第二十三次会议相关事项的事前认可意见
Regulatory Filings
2021-03-17 Chinese
百奥泰2020年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as materials for the 2020 Annual General Meeting (AGM) of 百奥泰生物制药股份有限公司. It includes detailed agenda items for the AGM, such as proposals regarding the 2020 Annual Report, Board of Directors work report, independent directors' report, financial statements, profit distribution plan, remuneration plan for 2021, reappointment of the accounting firm, and supervisory board report. The document contains meeting instructions, agenda, and attachments of reports to be discussed at the AGM. It is clearly a set of presentations and materials prepared for the AGM rather than the actual annual report or financial statements themselves. The length (15,000 characters) and detailed meeting procedural content confirm it is not a brief announcement or a certification. Therefore, the document fits the category of AGM Information (AGM-R).
2021-03-17 Chinese
百奥泰关于公司2021年度董事、监事和高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2021 annual remuneration scheme for the company's directors, supervisors, and senior management. It details the salary arrangements and independent directors' opinions on the remuneration plan. It references compliance with company law and governance codes but does not contain financial statements or detailed financial performance data. The document is a formal announcement of remuneration information rather than a full remuneration report or proxy statement. Therefore, it fits best under the category of Remuneration Information (DEF 14A). The document length and content confirm it is not a brief notice or a full annual report but a remuneration disclosure.
2021-03-04 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.